Katarzyna Tomczak

Katarzyna Tomczak

Auto-generated profile, based on publicly available information

Katarzyna Tomczak

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2021 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Open access
PDF file
ADAbhijeet Deshmukh
Abhijeet Deshmukh
SVSuhas V. Vasaikar
Suhas V. Vasaikar
KTKatarzyna Tomczak
Katarzyna Tomczak
STShubham Tripathi
Shubham Tripathi
PHPetra Den Hollander
Petra Den Hollander
SMSendurai Mani
Sendurai Mani
Significance: The epithelial-to-mesenchymal transition (EMT) is a critical cell biological process that occurs during normal embryonic development and cancer progression. Our study combines single-cell RNA-sequencing analysis and mathematical modeling to identify critical regulators of EMT. Detailed analyses of TGF-β1–induced EMT by single-cell RNA-sequencing data revealed simultaneous activation of EMT signaling pathways. We created mathematical approaches to identify the master regulatory pathway of EMT and key downstream mediators of this process. This study sheds light on the signaling architecture that governs EMT and informs ongoing efforts to delineate drivers of cancer initiation, progression, and metastasis.

23 January 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AOAbdullah A. Osman
Abdullah A. Osman
EAEmre Arslan
Emre Arslan
MBMason Bartels
Mason Bartels
CMChieko Michikawa
Chieko Michikawa
ALAntje Lindemann
Antje Lindemann
JMJeffrey Myers
Jeffrey Myers
Purpose: Cisplatin (CDDP)-based chemotherapy is a first-line treatment for patients with advanced head and neck squamous cell carcinomas (HNSCC), despite a high rate of treatment failures, acquired resistance, and subsequent aggressive behavior. The purpose of this study was to study the mechanism of CDDP resistance and metastasis in HNSCC. We investigated the role of NRF2 pathway activation as a driven event for tumor progression and metastasis of HNSCC. Experimental Design: Human HNSCC cell lines that are highly resistant to CDDP were generated. Clonogenic survival assays and a mouse model of oral cancer were used to examine the impact of NRF2 activation in vitro and in vivo on CDDP sensitivity and development of metastasis. Western blotting, immunostaining, whole-exome sequencing, single-cell transcriptomic and epigenomic profiling platforms were performed to dissect clonal evolution and molecular mechanisms. Results: Implantation of CDDP-resistant HNSCC cells into the tongues of nude mice resulted in a very high rate of distant metastases. The CDDP-resistant cells had significantly higher expression of NRF2 pathway genes in the presence of newly acquired KEAP1 mutations, or via epigenomic activation of target genes. Knockdown of NRF2 or restoration of the wild-type KEAP1 genes resensitized resistant cells to CDDP and decreased distant metastasis (DM). Finally, treatment with inhibitor of glutaminase-1, a NRF2 target gene, alleviated CDDP resistance. Conclusions: CDDP resistance and development of DM are associated with dysregulated and epigenetically reprogrammed KEAP1–NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP-resistant head and neck tumors.

18 February 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CCCaitlin A. Creasy
Caitlin A. Creasy
YMYuzhong Meng
Yuzhong Meng
MFMarie-Andrée Forget
Marie-Andrée Forget
TKTatiana Karpinets
Tatiana Karpinets
KTKatarzyna Tomczak
Katarzyna Tomczak
CBChantale Bernatchez
Chantale Bernatchez
Purpose: Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TIL) historically yields a 40%–50% response rate in metastatic melanoma. However, the determinants of outcome are largely unknown. Experimental Design: We investigated tumor-based genomic correlates of overall survival (OS), progression-free survival (PFS), and response to therapy by interrogating tumor samples initially collected to generate TIL infusion products. Results: Whole-exome sequencing (WES) data from 64 samples indicated a positive correlation between neoantigen load and OS, but not PFS or response to therapy. RNA sequencing analysis of 34 samples showed that expression of PDE1C, RTKN2, and NGFR was enriched in responders who had improved PFS and OS. In contrast, the expression of ELFN1 was enriched in patients with unfavorable response, poor PFS and OS, whereas enhanced methylation of ELFN1 was observed in patients with favorable outcomes. Expression of ELFN1, NGFR, and PDE1C was mainly found in cancer-associated fibroblasts and endothelial cells in tumor tissues across different cancer types in publicly available single-cell RNA sequencing datasets, suggesting a role for elements of the tumor microenvironment in defining the outcome of TIL therapy. Conclusions: Our findings suggest that transcriptional features of melanomas correlate with outcomes after TIL therapy and may provide candidates to guide patient selection.

21 July 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
HFHuiHui Fan
HuiHui Fan
FWFeng Wang
Feng Wang
AZAndy Zeng
Andy Zeng
AMAlex Murison
Alex Murison
KTKatarzyna Tomczak
Katarzyna Tomczak
HAHussein A. Abbas
Hussein A. Abbas
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by high rate of therapy resistance. Since the cell of origin can impact response to therapy, it is crucial to understand the lineage composition of AML cells at time of therapy resistance. Here we leverage single-cell chromatin accessibility profiling of 22 AML bone marrow aspirates from eight patients at time of therapy resistance and following subsequent therapy to characterize their lineage landscape. Our findings reveal a complex lineage architecture of therapy-resistant AML cells that are primed for stem and progenitor lineages and spanning quiescent, activated and late stem cell/progenitor states. Remarkably, therapy-resistant AML cells are also composed of cells primed for differentiated myeloid, erythroid and even lymphoid lineages. The heterogeneous lineage composition persists following subsequent therapy, with early progenitor-driven features marking unfavorable prognosis in The Cancer Genome Atlas AML cohort. Pseudotime analysis further confirms the vast degree of heterogeneity driven by the dynamic changes in chromatin accessibility. Our findings suggest that therapy-resistant AML cells are characterized not only by stem and progenitor states, but also by a continuum of differentiated cellular lineages. The heterogeneity in lineages likely contributes to their therapy resistance by harboring different degrees of lineage-specific susceptibilities to therapy.

26 November 2024 in Molecular Carcinogenesis
Verified
Journal Article
Open access
KTKatarzyna Tomczak
Katarzyna Tomczak
MPManishkumar S. Patel
Manishkumar S. Patel
ABAngela D. Bhalla
Angela D. Bhalla
CPChristine Peterson
Christine Peterson
SLSharon M. Landers
Sharon M. Landers
KTKeila E. Michael Torres
Keila E. Michael Torres
Malignant peripheral nerve sheath tumor (MPNST) development is characterized by an altered DNA methylation landscape, which presents a promising area for developing MPNST‐specific biomarkers for screening patients with NF1. Genome‐wide DNA methylation profiling of a cohort of 13 patients with MPNST (29 samples of tumor and adjacent neurofibroma tissues) and of NF1‐MPNST cell lines was performed to identify and validate candidate MPNST‐specific CpG sites (CpGs). A logistic regression prediction model was constructed to select MPNST‐specific CpGs distinct from adjacent neurofibromas and normal tissues. To test if hypermethylation at selected CpGs can also be detected in plasma from patients with MPNST, cfMBD‐seq was applied to profile the cfDNA methylome of blood from patients with MPNST and NF1. Based on stringent feature‐selection criteria and predictive modeling, we identified 73 candidate MPNST‐specific CpGs (67 with unique CpG island locations) that reliably discriminated MPNSTs from neurofibromas. Validation of five candidate biomarkers confirmed successful MPNST detection (sensitivity: > 88%, specificity: > 91%) in tissues. In plasma samples, 63 of 67 selected genomic regions had greater than 1.2‐fold higher methylation in patients with MPNST than those with NF1. Further, we identified 15 CpG islands that consistently separated plasma from patients with confirmed MPNST diagnosis from plasma of individuals with NF1 without a diagnosis of malignant transformation (FDR < 0.1). Our findings confirmed a unique hypermethylation pattern present during malignant transformation. This study highlights the potential to be investigated further as biomarkers in clinical settings for early MPNST detection in patients with NF1.

17 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NLNejla Ozirmak Lermi
Nejla Ozirmak Lermi
MAMax Molina Ayala
Max Molina Ayala
SHSharia Hernandez
Sharia Hernandez
WLWei Lu
Wei Lu
KKKhaja Khan
Khaja Khan
LSLuisa Maren Solis Soto
Luisa Maren Solis Soto
Imaging-based spatial transcriptomics (ST) is evolving rapidly as a pivotal technology in studying the biology of tumors and their associated microenvironments. However, the strengths of the commercially available ST platforms in studying spatial biology have not been systematically evaluated using rigorously controlled experiments. In this study, we used serial 5-m sections of formalin-fixed, paraffin-embedded surgically resected lung adenocarcinoma and pleural mesothelioma tumor samples in tissue microarrays to compare the performance of the single cell ST platforms CosMx, MERFISH, and Xenium (uni/multi-modal) platforms in reference to bulk RNA sequencing, multiplex immunofluorescence, GeoMx Digital Spatial Profiler, and hematoxylin and eosin staining data for the same samples. In addition to objective assessment of automatic cell segmentation and phenotyping, we performed pixel-resolution manual evaluation of phenotyping to carry out pathologically meaningful comparison between ST platforms. Our study detailed the intricate differences between the ST platforms, revealed the importance of parameters such as tissue age and probe design in determining the data quality, and suggested reliable workflows for accurate spatial profiling and molecular discovery.